The investigators propose to study the neurocircuitry of suicidal thoughts, regardless of whether or not depression is present.
Open-label diagnostic Phase III study using a single ketamine infusion to probe reward-circuitry and suicidal ideation in patients and including healthy control comparisons; neuroimaging (MRI) endpoints collected.
Primary aim is to characterise the neurobiology of suicidal thoughts independent of depression; clinical safety screening, ECG and lab monitoring, and follow-up per protocol.
Single open-label ketamine infusion (patients and healthy controls).
Single open-label ketamine infusion; dose per protocol (not specified in registry fragment).